Leerink Partnrs Weighs in on NRIX Q3 Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Investment analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for Nurix Therapeutics in a note issued to investors on Monday, March 17th. Leerink Partnrs analyst F. Khurshid expects that the company will earn ($0.96) per share for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q4 2025 earnings at ($1.00) EPS, FY2025 earnings at ($3.79) EPS and FY2026 earnings at ($3.32) EPS.

A number of other equities research analysts have also issued reports on the stock. Stephens reissued an “overweight” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, January 21st. BMO Capital Markets began coverage on shares of Nurix Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $35.00 price objective for the company. Stifel Nicolaus upped their price objective on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Royal Bank of Canada upped their price objective on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Finally, Needham & Company LLC lowered their target price on shares of Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Three equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.88.

Nurix Therapeutics Trading Down 6.3 %

Shares of NRIX opened at $12.99 on Thursday. Nurix Therapeutics has a 12-month low of $11.90 and a 12-month high of $29.56. The firm has a 50-day moving average price of $17.00 and a 200 day moving average price of $20.80. The firm has a market capitalization of $985.77 million, a P/E ratio of -4.49 and a beta of 2.18.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%.

Insider Activity

In related news, CFO Houte Hans Van sold 2,811 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $55,798.35. Following the sale, the chief financial officer now owns 39,549 shares of the company’s stock, valued at $785,047.65. This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gwenn Hansen sold 3,690 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the sale, the insider now directly owns 55,937 shares in the company, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 12,326 shares of company stock valued at $213,449. 7.20% of the stock is currently owned by company insiders.

Institutional Trading of Nurix Therapeutics

Several hedge funds have recently added to or reduced their stakes in NRIX. The Manufacturers Life Insurance Company raised its holdings in Nurix Therapeutics by 2.1% during the fourth quarter. The Manufacturers Life Insurance Company now owns 31,025 shares of the company’s stock worth $585,000 after purchasing an additional 642 shares in the last quarter. Corebridge Financial Inc. grew its position in shares of Nurix Therapeutics by 2.3% in the 4th quarter. Corebridge Financial Inc. now owns 34,907 shares of the company’s stock valued at $658,000 after buying an additional 770 shares during the last quarter. Kennedy Capital Management LLC raised its stake in Nurix Therapeutics by 0.7% during the 4th quarter. Kennedy Capital Management LLC now owns 114,623 shares of the company’s stock worth $2,159,000 after acquiring an additional 785 shares in the last quarter. US Bancorp DE lifted its position in Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after acquiring an additional 842 shares during the last quarter. Finally, Summit Investment Advisors Inc. lifted its position in Nurix Therapeutics by 13.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock valued at $138,000 after acquiring an additional 877 shares during the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.